Rhumbline Advisers Novo Cure LTD Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Novo Cure LTD stock. As of the latest transaction made, Rhumbline Advisers holds 142,354 shares of NVCR stock, worth $4.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
142,354
Previous 150,119 5.17%
Holding current value
$4.38 Million
Previous $2.57 Million 13.5%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$15.61 - $23.34 $121,211 - $181,235
-7,765 Reduced 5.17%
142,354 $2.22 Million
Q2 2024

Aug 01, 2024
BUY
$11.83 - $24.05 $442,016 - $898,604
37,364 Added 33.14%
150,119 $2.57 Million
Q1 2024

May 09, 2024
SELL
$12.42 - $17.29 $161,087 - $224,251
-12,970 Reduced 10.32%
112,755 $1.76 Million
Q4 2023

Feb 08, 2024
SELL
$11.13 - $15.78 $14,469 - $20,514
-1,300 Reduced 1.02%
125,725 $1.88 Million
Q3 2023

Nov 09, 2023
SELL
$16.15 - $42.35 $98,385 - $257,996
-6,092 Reduced 4.58%
127,025 $2.05 Million
Q2 2023

Aug 08, 2023
BUY
$40.29 - $82.51 $618,572 - $1.27 Million
15,353 Added 13.04%
133,117 $5.52 Million
Q1 2023

May 11, 2023
BUY
$56.44 - $118.81 $702,452 - $1.48 Million
12,446 Added 11.82%
117,764 $7.08 Million
Q4 2022

Feb 14, 2023
BUY
$63.98 - $85.37 $153,104 - $204,290
2,393 Added 2.32%
105,318 $7.73 Million
Q3 2022

Nov 10, 2022
BUY
$67.99 - $89.57 $389,922 - $513,683
5,735 Added 5.9%
102,925 $7.82 Million
Q2 2022

Aug 11, 2022
BUY
$56.6 - $89.9 $536,624 - $852,341
9,481 Added 10.81%
97,190 $6.76 Million
Q1 2022

May 12, 2022
SELL
$60.15 - $84.52 $616,778 - $866,668
-10,254 Reduced 10.47%
87,709 $7.27 Million
Q4 2021

Feb 10, 2022
BUY
$75.08 - $121.99 $291,085 - $472,955
3,877 Added 4.12%
97,963 $7.36 Million
Q3 2021

Nov 12, 2021
SELL
$116.17 - $194.55 $67,030 - $112,255
-577 Reduced 0.61%
94,086 $10.9 Million
Q2 2021

Aug 05, 2021
SELL
$130.4 - $225.58 $496,954 - $859,685
-3,811 Reduced 3.87%
94,663 $21 Million
Q1 2021

May 06, 2021
SELL
$124.11 - $190.17 $745,901 - $1.14 Million
-6,010 Reduced 5.75%
98,474 $13 Million
Q4 2020

Feb 10, 2021
SELL
$112.16 - $174.14 $149,284 - $231,780
-1,331 Reduced 1.26%
104,484 $18.1 Million
Q3 2020

Nov 12, 2020
SELL
$58.05 - $111.31 $372,100 - $713,497
-6,410 Reduced 5.71%
105,815 $11.8 Million
Q2 2020

Aug 13, 2020
SELL
$57.2 - $74.41 $524,524 - $682,339
-9,170 Reduced 7.55%
112,225 $6.66 Million
Q1 2020

May 06, 2020
BUY
$57.05 - $95.75 $456 - $766
8 Added 0.01%
121,395 $8.18 Million
Q4 2019

Feb 05, 2020
BUY
$68.3 - $93.8 $471,474 - $647,501
6,903 Added 6.03%
121,387 $10.2 Million
Q3 2019

Oct 23, 2019
SELL
$61.86 - $97.8 $16,269 - $25,721
-263 Reduced 0.23%
114,484 $8.56 Million
Q2 2019

Aug 14, 2019
BUY
$42.22 - $63.23 $720,146 - $1.08 Million
17,057 Added 17.46%
114,747 $7.26 Million
Q1 2019

May 01, 2019
BUY
$31.96 - $56.12 $68,873 - $120,938
2,155 Added 2.26%
97,690 $4.71 Million
Q4 2018

Jan 31, 2019
BUY
$28.72 - $52.63 $853,414 - $1.56 Million
29,715 Added 45.15%
95,535 $3.2 Million
Q3 2018

Nov 07, 2018
SELL
$32.0 - $52.4 $106,912 - $175,068
-3,341 Reduced 4.83%
65,820 $3.45 Million
Q2 2018

Aug 06, 2018
BUY
$19.85 - $32.0 $290,822 - $468,832
14,651 Added 26.88%
69,161 $2.17 Million
Q1 2018

May 02, 2018
SELL
$19.3 - $23.65 $16,019 - $19,629
-830 Reduced 1.5%
54,510 $1.19 Million
Q4 2017

Feb 09, 2018
SELL
$16.3 - $21.9 $168,199 - $225,986
-10,319 Reduced 15.72%
55,340 $1.12 Million
Q3 2017

Nov 06, 2017
BUY
$18.05 - $21.75 $1.19 Million - $1.43 Million
65,659
65,659 $1.3 Million

Others Institutions Holding NVCR

# of Institutions
263
Shares Held
77M
Call Options Held
1.17M
Put Options Held
318K
View Full List

About NovoCure Ltd

NVCR Quotes by TradingView
  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.23B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email